Histogen Inc. (HSTO) Prices $14M Upsized Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast to split cable business from media in NBCUniversal, Sky spinoff
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Histogen Announces Pricing of $14.0 Million Upsized Public Offering
December 30, 2020 10:26 PM ESTSAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that it has it has priced a public offering of an aggregate of 14,000,000 shares of common stock (or common stock equivalents offered through the issuance of pre-funded warrants), together with accompanying warrants to purchase up to an aggregate of 14,000,000 shares of common stock, at an effective public offering price of $1.00 per share and accompanying warrant.... More
